-
公开(公告)号:US09206200B2
公开(公告)日:2015-12-08
申请号:US14117341
申请日:2012-05-11
IPC分类号: C07D519/00 , C07D417/04 , C07D471/08 , C07D401/14 , C07D405/14 , C07D401/06 , C07D401/08 , C07D403/06 , C07D403/08 , C07D417/08 , C07D471/04 , C07D487/08 , C07D491/10 , C07D209/64
CPC分类号: C07D519/00 , C07D209/64 , C07D401/06 , C07D401/08 , C07D401/14 , C07D403/06 , C07D403/08 , C07D405/14 , C07D417/08 , C07D471/04 , C07D471/08 , C07D487/08 , C07D491/10
摘要: The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及通式(I)的N-连接的内酰胺类化合物,其为M1受体阳性变构调节剂,可用于治疗涉及M1受体的疾病,例如阿尔茨海默病,精神分裂症,疼痛或 睡眠障碍 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
2.
公开(公告)号:US20150065498A1
公开(公告)日:2015-03-05
申请号:US14117341
申请日:2012-05-11
IPC分类号: C07D519/00 , C07D471/04 , C07D471/08 , C07D209/64 , C07D403/06 , C07D405/14 , C07D401/14 , C07D401/06
CPC分类号: C07D519/00 , C07D209/64 , C07D401/06 , C07D401/08 , C07D401/14 , C07D403/06 , C07D403/08 , C07D405/14 , C07D417/08 , C07D471/04 , C07D471/08 , C07D487/08 , C07D491/10
摘要: The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及通式(I)的N-连接的内酰胺类化合物,其为M1受体阳性变构调节剂,可用于治疗涉及M1受体的疾病,例如阿尔茨海默病,精神分裂症,疼痛或 睡眠障碍 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号:US08697690B2
公开(公告)日:2014-04-15
申请号:US13805346
申请日:2011-06-27
IPC分类号: C07D209/62 , C07D405/04 , C07D401/14 , C07D471/04 , C07D401/10 , C07D405/14
CPC分类号: C07D209/62 , C07D209/64 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/04 , C07D405/14 , C07D471/04
摘要: The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及式(I)的异吲哚酮化合物,其为M1受体阳性变构调节剂,可用于治疗涉及M1受体的疾病,例如阿尔茨海默氏病,精神分裂症,疼痛或睡眠障碍。 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号:US20130109686A1
公开(公告)日:2013-05-02
申请号:US13805346
申请日:2011-06-27
IPC分类号: C07D209/62 , C07D405/04 , C07D401/14 , C07D471/04 , C07D401/10 , C07D405/14
CPC分类号: C07D209/62 , C07D209/64 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/04 , C07D405/14 , C07D471/04
摘要: The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及式(I)的异吲哚酮化合物,其为M1受体阳性变构调节剂,可用于治疗涉及M1受体的疾病,例如阿尔茨海默氏病,精神分裂症,疼痛或睡眠障碍。 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号:US20110112064A1
公开(公告)日:2011-05-12
申请号:US13008161
申请日:2011-01-18
申请人: James C. Barrow , Kelly-Ann S. Bieber , Rowena V. Cube , Mamio Christa Mattern , Thomas S. Reger , Youheng Shu , Zhi-Qiang Yang
发明人: James C. Barrow , Kelly-Ann S. Bieber , Rowena V. Cube , Mamio Christa Mattern , Thomas S. Reger , Youheng Shu , Zhi-Qiang Yang
IPC分类号: A61K31/4439 , A61K31/44 , A61K31/444 , A61K31/4436 , A61K31/5377 , A61K31/541 , A61P25/08 , A61P29/00 , A61P25/16 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/30
CPC分类号: C07D413/12 , C07D213/40 , C07D213/61 , C07D213/65 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D411/12
摘要: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
摘要翻译: 本发明涉及作为T型钙通道拮抗剂的吡啶酰胺化合物,其可用于治疗或预防其中涉及T型钙通道的疾病和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及T型钙通道的疾病中的用途。
-
公开(公告)号:US20100249176A1
公开(公告)日:2010-09-30
申请号:US12739203
申请日:2008-10-23
申请人: James C. Barrow , Thomas S. Reger , Youheng Shu , Zhi-Qiang Yang
发明人: James C. Barrow , Thomas S. Reger , Youheng Shu , Zhi-Qiang Yang
IPC分类号: A61K31/437 , C07D405/12 , C07D413/12 , C07D401/12 , C07D471/04 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61P25/08 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P25/18
CPC分类号: C07D405/12 , C07D401/12 , C07D413/12 , C07D487/04
摘要: The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
摘要翻译: 本发明涉及作为T型钙通道拮抗剂的杂环酰胺化合物,其可用于治疗或预防涉及T型钙通道的疾病和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及T型钙通道的疾病中的用途。
-
公开(公告)号:US08637513B2
公开(公告)日:2014-01-28
申请号:US12739294
申请日:2008-10-23
申请人: James C. Barrow , Paul J. Coleman , Thomas S. Reger , Kelly-Ann S. Schlegel , Youheng Shu , Zhi-Qiang Yang
发明人: James C. Barrow , Paul J. Coleman , Thomas S. Reger , Kelly-Ann S. Schlegel , Youheng Shu , Zhi-Qiang Yang
IPC分类号: C07D401/12 , A61K31/517 , A61K31/497 , A61K31/4439 , C07D487/04 , A61K31/5025 , C07D413/12 , A61K31/443 , C07D417/12 , A61K31/4436 , C07D213/63 , C07D239/74 , C07D241/36 , C07D471/02 , A61P25/08 , A61P29/00 , A61P25/18 , A61P25/16 , A61P25/24 , A61P25/22 , A61P9/08 , A61P9/12 , A61P35/00 , A61P31/10
CPC分类号: C07D401/12 , C07D213/65 , C07D405/12 , C07D413/12 , C07D417/12 , C07D487/04
摘要: The present invention is directed to heterocycle phenyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
摘要翻译: 本发明涉及作为T型钙通道拮抗剂的杂环苯酰胺化合物,其可用于治疗或预防涉及T型钙通道的疾病和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及T型钙通道的疾病中的用途。
-
公开(公告)号:US20100261724A1
公开(公告)日:2010-10-14
申请号:US12739294
申请日:2008-10-23
申请人: James C. Barrow , Paul J. Coleman , Thomas S. Reger , Kelly-Ann S. Schlegel , Youheng Shu , Zhi-Qiang Yang
发明人: James C. Barrow , Paul J. Coleman , Thomas S. Reger , Kelly-Ann S. Schlegel , Youheng Shu , Zhi-Qiang Yang
IPC分类号: A61K31/5025 , C07D401/12 , A61K31/517 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , A61K31/497 , A61K31/4439 , C07D487/04 , C07D413/12 , A61K31/443 , C07D405/12 , C07D417/12 , A61K31/437 , C07D471/04
CPC分类号: C07D401/12 , C07D213/65 , C07D405/12 , C07D413/12 , C07D417/12 , C07D487/04
摘要: The present invention is directed to heterocycle phenyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
摘要翻译: 本发明涉及作为T型钙通道拮抗剂的杂环苯酰胺化合物,其可用于治疗或预防涉及T型钙通道的疾病和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及T型钙通道的疾病中的用途。
-
公开(公告)号:US09199939B2
公开(公告)日:2015-12-01
申请号:US13515724
申请日:2010-12-13
IPC分类号: C07D401/06 , C07D215/48 , C07D215/60 , C07D409/14 , C07D413/06 , C07D405/12 , C07D401/14 , C07D413/14 , C07D405/14 , C07D417/14
CPC分类号: C07D215/60 , C07D215/48 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04
摘要: The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及作为M1受体阳性变构调节剂的式(I)的喹啉酰胺化合物,其可用于治疗涉及M1受体的疾病,例如阿尔茨海默氏病,精神分裂症,疼痛或睡眠障碍。 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号:US20120252808A1
公开(公告)日:2012-10-04
申请号:US13515724
申请日:2010-12-13
IPC分类号: A61K31/4709 , C07D405/12 , A61K31/506 , A61K31/47 , C07D413/04 , A61K31/5377 , C07D401/04 , A61K31/497 , A61K31/501 , C07D471/04 , A61K31/437 , A61P25/28 , A61P25/18 , A61P29/00 , A61P25/00 , C07D215/14
CPC分类号: C07D215/60 , C07D215/48 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04
摘要: The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及作为M1受体阳性变构调节剂的式(I)的喹啉酰胺化合物,其可用于治疗涉及M1受体的疾病,例如阿尔茨海默氏病,精神分裂症,疼痛或睡眠障碍。 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
-
-
-
-
-
-
-
-